<DOC>
	<DOCNO>NCT00815464</DOCNO>
	<brief_summary>Study Purpose : The purpose study assess Liquid Acupuncture ( Herb Acupoints Injection ) Therapeutics could achieve permanent efficacy response Chronic Hepatitis B. Efficacy Assessment : At cessation Treatment ( 24 week ) compare Testing Data Normal Criteria individual baseline.Continue monitor Status 1-5 year . Data Analysis : Each 4 week collect Patients ' test data fill table.A summary table present frequency table categorical variable number percentage .</brief_summary>
	<brief_title>A Single-Arm Study Evaluating Efficacy Liquid Acupuncture Therapeutics Chronic Hepatitis B</brief_title>
	<detailed_description>Inclusion Criteria &amp; Outcome : Documented chronic hepatitis B infection positive serum HBV-DNA 10^5 copies/mL &amp; . Permanent efficacy response whole treatment circle close ( 24 week , someone may later 24 week within 48 week ) - HBeAg loss ( HBeAg positive ) - Liver Function normal ( Liver Function normal ) - HBV DNA non-detectability ( PCR &lt; 500 copies/ml ) - Image chronic diffuse hepatic disease recover normal . - HBsAg titer decrease continually loss cessation treatment . Treatment Procedure : Patients involve study 24-48 week enrollment . There external sponsor , commercial sponsor governmental agency study . The study conduct Dr. Yu , Ke Heng , master Liquid Acupuncture ( Herb Acupoint Injection ) practice 30 years.About 30 subject involve study overall . All subject fill worldwide . Patients required rent apartment house stay city ( Xiamen city , China prefer ) .Dr . Yu go Patients ' site treatment practice weekly , 4 week one circle ( first 3 week treatment practice last week Test collection ) .Appointed Hospitals test must certificate qualified ( Chang Gang Hospital prefer ) .Dr . Yu explain test result individually .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Coal Tar</mesh_term>
	<criteria>Male female subject age 1855 year inclusive . Documented chronic hepatitis B infection determine presence serum HBsAg least 6 month . Serum HBV DNA ≥ 10^4 copies/mL ( PRC ) . Use interferon alfa , thymosin , antiviral agent less 1 year receive 2 month . ( If expect stop agent worry risk , may ask u help . ) Agree participate investigational trial undertake HBV systemic antiviral regimen participation study . Able give write informed consent comply requirement study . Superinfection/Coinfection hepatitis A , hepatitis C , hepatitis D , hepatitis E HIV . Autoimmune hepatitis ( antinuclear antibody titre &gt; 1:160 ) . Use interferon alfa , thymosin , antiviral agent 1 year . Pregnant nursing . Any serious active medical psychiatric illness hepatitis B , opinion investigator , would interfere patient treatment , assessment compliance protocol . This would include , may limit , renal , cardiac , pulmonary , vascular , neurogenic , digestive , metabolic ( diabetes , thyroid disorder , adrenal disease ) , immunodeficiency disorder , active infection cancer . Clinical sign decompensated liver disease baseline . These may include limited : serum bilirubin &gt; 2.5 mg/dL ( ≤ 43 µmol/L ) , prothrombin time &gt; 2 second prolonged ULN , serum albumin &lt; 35g/L , history ascites , variceal bleeding , encephalopathy , Alanine aminotransferase ( ALT ) &gt; 10 time ULN screen history acute exacerbation lead transient decompensation . Hepatocellular carcinoma evidence one following : suspicious focus ultrasound radiological examination . positive ultrasound finding , serum alphafetoprotein &gt; 100ng/mL Active alcohol drug abuse history alcohol drug abuse consider investigator sufficient hinder compliance treatment , participation study interpretation result . Received hepatotoxic drug ( e.g. , anabolic steroid , ketaconazole , itraconazole , isoniazid , rifampin , rifabutin ) within 2 month prior study screen expect receive course study . Received nephrotoxic drug ( e.g. , aminoglycosides , amphotericin B , vancomycin , cidofovir , foscarnet , cisplatinum , pentamidine etc . ) competitor renal excretion ( e.g. , probenecid ) within 2 month prior study screen expectation patient receive course study . Receiving systemic ( intravenous oral ) steroid , immunosuppressant therapy chemotherapeutic agent within 2 month study screen expect receive agent course study . Neutrophile granulocyte count &lt; 1.0*10e9/L Platelet count &lt; 30*10e9/L . Inability comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>Liquid Acupuncture ( Herb Acupoint Injection )</keyword>
	<keyword>Therapeutics</keyword>
	<keyword>Herbalist</keyword>
	<keyword>Acupoint</keyword>
</DOC>